Citizens JMP lowered the firm’s price target on Structure Therapeutics (GPCR) to $87 from $89 and keeps an Outperform rating on the shares following the Q2 report. The firm says the company will release the Phase 2b data for aleniglipron by the end of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Reports Q2 2025 Financial Results
- Promising Developments in Structure Therapeutics’ Clinical Trials Drive Buy Rating
- Structure Therapeutics files automatic mixed securities shelf
- Structure Therapeutics initiated with a Buy at Clear Street
- Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs